Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey

This study has been completed.

First Received: April 15, 2008 Last Updated: May 22, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00660712

Purpose

A registry study to identify the patient-diagnosis-treatment characteristic profile of patients with bipolar disorder in Turkey.

Condition
Bipolar Disorder

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Evaluation of Patient Characteristics and Treatment Approaches to Patients With Bipolar Disorder in Turkey

Resource links provided by NLM:

MedlinePlus related topics: Bipolar Disorder

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Identification of the patient-diagnosis-treatment characteristic profile of patients with bipolar disorder in Turkey. [ Designated as safety issue: No ]

Secondary Outcome Measures:

Evaluation of the time period that elapsed since the diagnosis of bipolar disorder [ Designated as safety issue: No ]
Evaluation of co-morbid psychiatric diseases [ Designated as safety issue: No ]
Identification of treatment modalities selected according to the disease phase [ Designated as safety issue: No ]
Identification of the number of first degree relatives diagnosed with bipolar disorder [ Designated as safety issue: No ]
Evaluation of the relationship between patient and disease characteristics [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Groups/Cohorts
1 Patients with bipolar disorder

Eligibility

Study Population

Speciality care outpatient clinic (Psychiatry outpatient clinic)

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00660712

Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:

Mustafa Bilici, MD, Assoc. Prof

Erenkoy State Hospital for Psychiatric Diseases, Istanbul, Turkey

More Information

No publications provided

Study ID Numbers:	NIS-NTR-DUM-2007/1
Study First Received:	April 15, 2008
Last Updated:	May 22, 2009
ClinicalTrials.gov Identifier:	NCT00660712 History of Changes
Health Authority:	Turkey: Ministry of Health

Keywords provided by AstraZeneca:

Bipolar disorder
patient characteristics
treatment characteristics

Additional relevant MeSH terms:

Affective Disorders, Psychotic
Pathologic Processes
Disease

Mental Disorders
Bipolar Disorder
Mood Disorders

ClinicalTrials.gov processed this record on February 08, 2010